Compare VRRM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRRM | SYRE |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | N/A | 2016 |
| Metric | VRRM | SYRE |
|---|---|---|
| Price | $18.67 | $33.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $27.70 | ★ $56.50 |
| AVG Volume (30 Days) | ★ 1.5M | 591.6K |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $942,717,000.00 | N/A |
| Revenue This Year | $11.68 | N/A |
| Revenue Next Year | $6.32 | N/A |
| P/E Ratio | $58.26 | ★ N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $17.08 | $10.91 |
| 52 Week High | $26.89 | $35.58 |
| Indicator | VRRM | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 28.50 | 53.23 |
| Support Level | $18.35 | $30.92 |
| Resistance Level | $19.02 | $35.58 |
| Average True Range (ATR) | 0.75 | 1.86 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 27.81 | 55.42 |
Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three segments namely Commercial Services, Government Solutions, and Parking Solutions. It generates maximum revenue from the Commercial Services segment. The commercial Services segment delivers tolling and violation management services to rental car companies, commercial fleet vehicle owners, and violation issuing authorities.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.